Halle Berry Women's HRT: What Clinicians Should Tell Patients

What Halle Berry Has Said Publicly About Menopause and HRT

Halle Berry has become one of the most visible advocates for open conversation about menopause in American public life. She has discussed her perimenopause experience across multiple platforms and has been transparent about using hormone therapy.

In a 2023 interview with Vogue, Berry described being misdiagnosed with herpes at age 27 when her symptoms were, in fact, perimenopause. She has referenced working with physicians to manage symptoms including hot flashes, brain fog, and joint pain. Berry has discussed pellet therapy specifically, describing subcutaneous hormone pellets as part of her regimen, and has used her social media following to encourage women to seek care rather than accept suffering as inevitable.

Her public statements are advocacy, not medical advice. Clinicians should treat them as exactly that: a conversation-opener with patients, not a clinical protocol.

What She Has Not Said

Berry has not disclosed specific hormone formulations, pellet dosing, or her prescribing physicians' protocols. Any inference about her precise regimen goes beyond what she has shared publicly. This article does not speculate beyond her verified public statements.

Why Her Story Reaches the Exam Room

Roughly 1.3 million American women enter menopause each year, according to the CDC. A large proportion report that they first learned to seek treatment from a media source, a friend, or a celebrity. When a patient arrives citing Berry's experience, it signals engagement. That engagement is an opportunity, not a problem.

The Clinical Picture: Perimenopause, Menopause, and Hormone Therapy

Menopause is defined as 12 consecutive months of amenorrhea following the final menstrual period, typically occurring between ages 45 and 55 in the United States. Perimenopause can begin 7 to 10 years earlier and is characterized by erratic estradiol fluctuation, irregular cycles, and emerging vasomotor symptoms (VMS).

Symptom Burden Is Real and Measurable

The SWAN (Study of Women's Health Across the Nation) cohort followed 3,302 women across multiple racial and ethnic groups and found that 79% reported VMS lasting a median of 7.4 years, with some women experiencing symptoms for more than a decade (SWAN; Avis et al., JAMA Intern Med, 2015). Berry's reported symptom onset in her late 20s is atypical but not impossible; premature ovarian insufficiency (POI) affects approximately 1% of women under age 40 and may have been a factor worth evaluating in her history (Webber et al., Lancet, 2016).

HRT Reduces VMS Substantially

Hormone therapy remains the most effective intervention for VMS. A Cochrane systematic review of 24 trials (N=3,329) found that combined estrogen-progestogen therapy reduced the weekly frequency of hot flashes by 75-80% compared with placebo, with a standardized mean difference of -1.05 (95% CI -1.26 to -0.85) (Marjoribanks et al., Cochrane Database Syst Rev, 2017). That is a clinically meaningful reduction, not a marginal one.

The Menopause Society 2023 Position Statement

The Menopause Society (formerly NAMS) issued its 2023 Position Statement on hormone therapy, concluding that "for women aged younger than 60 years or within 10 years of menopause onset, the benefits of hormone therapy outweigh the risks for most women with bothersome VMS and no contraindications" (Menopause Society, Menopause, 2023). This is a direct quotation from a named guideline document, and it anchors the clinical recommendation that patients citing Berry's story deserve to hear.

Pellet Therapy: What the Evidence Shows

Pellet therapy is the delivery method Berry has referenced most directly. Subcutaneous pellets are small cylinders of compounded crystalline hormone, typically testosterone and sometimes estradiol, inserted under the skin of the buttock or hip by a clinician. They dissolve over 3 to 6 months.

Regulatory Status

No hormone pellet product carries FDA approval for menopause treatment in women. Pellets are compounded medications governed by Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. The FDA has stated that compounded products are not required to demonstrate safety or efficacy before use. This does not mean pellets are uniformly harmful, but it does mean the evidentiary bar differs substantially from FDA-approved products.

What the Clinical Literature Shows

Published data on pellet therapy are limited and largely retrospective. A 2019 systematic review in the journal Maturitas examined 5 studies on subcutaneous testosterone pellets in women and found evidence of benefit for libido and mood but noted that several studies reported supraphysiologic testosterone levels (above 150 ng/dL), which are associated with acne, hirsutism, voice changes, and clitoral enlargement (Glaser & Dimitrakakis, Maturitas, 2019; see also NCBI archive). No long-term cardiovascular or breast safety RCT data exist for pellet therapy in women.

Dosing Variability Is a Real Risk

Compounded pellets have no validated titration protocol. A 2020 analysis in Obstetrics and Gynecology found significant batch-to-batch variability in compounded hormone preparations, with some lots delivering up to 30% more hormone than labeled (Bhatt et al., Obstet Gynecol, 2020). Unlike transdermal patches or oral tablets, a pellet cannot be removed once inserted if a patient develops an adverse reaction.

The Honest Clinical Summary on Pellets

Pellet therapy may work for some patients. The mechanism is sound. The problem is that there is no strong randomized trial demonstrating safety superiority over FDA-approved options, dosing is not standardized, and supraphysiologic androgen exposure carries real downstream risk. Clinicians should present this picture transparently rather than dismissing pellets outright or endorsing them uncritically.

FDA-Approved Hormone Therapy Options for Midlife Women

Patients who come in citing Berry's experience deserve to know that multiple evidence-graded options exist. The following framework maps approved products to patient profiles.

Estrogen Delivery Routes

Oral estradiol (e.g., Estrace 0.5-2 mg daily) is the most studied formulation. Oral estrogen undergoes first-pass hepatic metabolism, raising sex hormone-binding globulin and triglycerides. It may not be optimal for women with clotting risk or hypertriglyceridemia.

Transdermal estradiol (patches such as Vivelle-Dot 0.025-0.1 mg/day; gels such as EstroGel; sprays such as Evamist) bypasses first-pass metabolism. Observational data from the E3N cohort (N=80,377) found that transdermal estradiol was not associated with increased venous thromboembolism risk, unlike oral estradiol (Canonico et al., Circulation, 2007). For women over 60 or with VTE risk factors, transdermal routes are generally preferred.

Vaginal estradiol (ring, tablet, cream) addresses genitourinary syndrome of menopause (GSM) with minimal systemic absorption. The Menopause Society recommends low-dose vaginal estrogen as first-line for women whose primary complaint is GSM rather than systemic VMS.

Progestogen Choice Matters

Women with a uterus require progestogen to protect the endometrium. Micronized progesterone (Prometrium 100-200 mg nightly) appears to carry a lower breast cancer signal than synthetic progestins. The E3N cohort found that estrogen combined with micronized progesterone was not associated with increased breast cancer risk at 5 years, while estrogen plus synthetic progestins was (Fournier et al., Breast Cancer Res Treat, 2008).

Testosterone for Women

The Endocrine Society's 2019 Clinical Practice Guideline on testosterone therapy in women concluded that the evidence supports testosterone use specifically for hypoactive sexual desire disorder (HSDD) in postmenopausal women, at doses that approximate premenopausal physiologic levels (total testosterone 20-40 ng/dL) (Islam et al., J Clin Endocrinol Metab, 2019). No FDA-approved systemic testosterone product exists for women in the United States. Off-label use of male formulations at one-tenth the male dose is common practice, though compounding remains an option with the caveats noted above.

The WHI Reassessment: What Clinicians Need to Communicate

The Women's Health Initiative (WHI) trial published in 2002 caused a dramatic drop in HRT prescribing that persisted for over a decade. Many patients, and some clinicians, still carry that fear. The reassessment changes the picture significantly.

A re-analysis by Manson et al. In JAMA (2013, N=27,347) stratified outcomes by age and time since menopause. Women aged 50-59 who initiated conjugated equine estrogen showed a non-significant trend toward reduced all-cause mortality (hazard ratio 0.69, 95% CI 0.48-1.00) compared with placebo (Manson et al., JAMA, 2013). The original WHI population was older (mean age 63) and more than 10 years past menopause, a group for whom HRT initiation carries a different risk calculus.

The "timing hypothesis," sometimes called the "window of opportunity," holds that HRT initiated within 10 years of menopause onset or before age 60 is associated with cardiovascular benefit, while initiation in older, longer-postmenopausal women may not carry the same benefit and may increase risk (Rossouw et al., JAMA, 2002, for original data; Manson et al., 2013, for stratified re-analysis). This distinction is clinically consequential and is the reason the Menopause Society 2023 Position Statement uses a 10-year or age-60 threshold.

Breast Cancer Risk in Context

Combined estrogen-progestogen therapy is associated with a small absolute increase in breast cancer risk. The WHI found an excess of approximately 8 cases per 10,000 women per year with combined therapy (Rossouw et al., JAMA, 2002). Estrogen-alone therapy (for hysterectomized women) was associated with a non-significant reduction in breast cancer in the WHI. The absolute risk increase with combined therapy is comparable to the risk associated with drinking one to two alcoholic drinks per day, a comparison that helps patients contextualize the number.

How to Counsel the Patient Who Cites Halle Berry

Patients who arrive mentioning Berry's story are already engaged. They are asking for help. The clinical response should validate the inquiry, address the evidence, and then move to shared decision-making.

Step One: Validate the Conversation

Acknowledge that Berry's advocacy has helped reduce stigma around menopause care. A short statement, something like "You are right that hormone therapy is an option we should talk through for you specifically," signals that the clinician is not going to dismiss the question.

Step Two: Take a Thorough Symptom and Risk Inventory

A baseline evaluation before prescribing any hormone therapy should include:

• VMS frequency and severity (a validated tool such as the Menopause-Specific Quality of Life questionnaire or the Greene Climacteric Scale)
• Menstrual history and age of onset of symptoms
• Personal and family history of breast cancer, VTE, cardiovascular disease, and stroke
• Baseline labs: FSH, estradiol, total and free testosterone, SHBG, CBC, CMP, fasting lipids
• Blood pressure measurement
• Pelvic exam and cervical cancer screening status
• Mammography status per USPSTF guidelines

Step Three: Present Options With Numbers, Not Generalizations

Patients respond better to specific information than to vague reassurance. A clinician might say: "For women your age with hot flashes, transdermal estradiol reduces symptom frequency by roughly 75 to 80 percent. The absolute added breast cancer risk with combined estrogen-progestogen over 5 years is about 4 to 8 extra cases per 10,000 women. Here is how that compares to your other risks." Then let the patient weigh that.

Step Four: Address Pellet Requests Specifically

If the patient specifically requests pellets because Berry mentioned them, the clinician can say: "Pellets may work, and some patients prefer them. The concern is that no standardized dosing protocol exists, some women end up with testosterone levels well above normal range, and we cannot remove a pellet if that happens. I would rather start with a form of therapy where we can adjust the dose immediately if needed." This is honest. It is not dismissive.

Step Five: Follow Up at 6 to 12 Weeks

Hormone therapy typically requires dose adjustment. A follow-up at 6 to 12 weeks allows for symptom reassessment, repeat labs (especially if testosterone was prescribed), and blood pressure re-check. The Menopause Society recommends annual reassessment of the benefit-risk balance and does not recommend routine discontinuation at a fixed age in the absence of new contraindications.

Genitourinary Syndrome of Menopause: A Commonly Missed Diagnosis

GSM affects up to 50% of postmenopausal women and includes vaginal dryness, dyspareunia, recurrent urinary tract infections, and urinary urgency (Portman & Gass, Menopause, 2014). Unlike VMS, GSM does not improve spontaneously over time. It worsens without treatment.

Low-dose vaginal estradiol (ring delivering 7.5 mcg/day, or vaginal tablet 10 mcg twice weekly) produces local tissue benefit with minimal systemic absorption and does not require concurrent progestogen even in women with a uterus at these doses, per the Menopause Society. Ospemifene (Osphena 60 mg oral daily), a selective estrogen receptor modulator, is also FDA-approved for moderate to severe dyspareunia from GSM and may suit women who prefer to avoid vaginal application (FDA label, Osphena).

Non-Hormonal Options for Women Who Cannot or Choose Not to Use HRT

Not every woman is a candidate for or interested in hormone therapy. Clinicians should be prepared with evidence-based non-hormonal alternatives.

Fezolinetant (Veozah 45 mg daily), a neurokinin 3 receptor antagonist, received FDA approval in May 2023 for moderate to severe VMS. In the SKYLIGHT 1 trial (N=501), fezolinetant reduced hot flash frequency by 62% at week 12 versus 45% with placebo (P<0.001) (FDA approval announcement). It is not a hormone and carries no associated breast cancer or VTE signal based on trial data to date.

Cognitive behavioral therapy (CBT) delivered in 4 to 6 sessions reduced VMS frequency by approximately 40% in the MENOS 2 RCT (N=96) (Ayers et al., Menopause, 2012). CBT also improved sleep and mood. It is underused and under-referred.

Paroxetine 7.5 mg (Brisdelle) is the only FDA-approved non-hormonal prescription treatment for VMS specifically. Other SSRIs and SNRIs are used off-label with modest evidence. Avoid paroxetine in women taking tamoxifen due to CYP2D6 inhibition.

What Clinicians Should Know About Compounding and Quality

Berry's reference to pellet therapy raises broader questions about compounded hormones that clinicians encounter regularly. Compounded bioidentical hormone therapy (cBHT) is chemically identical to endogenous hormones in molecular structure but is not subject to FDA efficacy and safety review before dispensing.

The National Academies of Sciences, Engineering, and Medicine issued a 2020 report concluding that "the evidence base for the safety and efficacy of cBHT is weak" and recommending that "cBHT should not be recommended for routine use in lieu of FDA-approved hormone therapy" (NASEM Report, 2020). This does not mean compounded hormones are always inappropriate. It means the evidence for FDA-approved formulations is more complete, and that should be the starting point for most patients.

Salivary hormone testing, often used to monitor pellet therapy, is not validated for this purpose. The Endocrine Society recommends serum assays for estradiol and testosterone monitoring (Endocrine Society Position Statement). Clinicians seeing patients transferred from pellet therapy practices should recheck levels via serum before assuming prior testing reflects true physiologic status.